What is iCAD?
Headquartered in Nashua, N.H., iCAD is dedicated to providing clinically proven AI-driven solutions that empower medical providers with enhanced accuracy and reliability in cancer detection. Their flagship ProFound Breast Health Suite offers advanced AI analysis for mammography, focusing on early detection, density assessment, and risk evaluation. This strategic investment is poised to accelerate the development and deployment of these critical technologies within the healthcare sector, reinforcing iCAD's position as an innovator in medical imaging and oncology.
How much funding has iCAD raised?
iCAD has raised a total of $37.8M across 3 funding rounds:
Share Placement
$15M
Stock Offering
$10.3M
Stock Offering
$12.5M
Share Placement (2012): $15M with participation from Deerfield
Stock Issuance/Offering (2019): $10.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $12.5M, investors not publicly disclosed
Key Investors in iCAD
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
What's next for iCAD?
With a significant strategic investment and a history of substantial capital raises, iCAD is well-positioned for accelerated growth and market expansion. The company's focus on AI for early cancer detection aligns with the increasing demand for advanced diagnostic tools in healthcare. Future endeavors will likely involve further refinement of their AI algorithms, expanding the ProFound Breast Health Suite's capabilities, and forging new partnerships to integrate their solutions into broader clinical workflows. This latest financing is expected to fuel innovation and solidify iCAD's leadership in the fight against cancer.
See full iCAD company page
